0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Other Articles |

CLINICAL OBSERVATIONS ON A NEW SULFONAMIDE (GANTRISIN®)

JOHN A. BIGLER, M.D.; ORVILLE THOMAS, M.D.
Am J Dis Child. 1950;79(5):785-790. doi:10.1001/archpedi.1950.04040010802001.
Text Size: A A A
Published online

G A N T R I S I N,® 3,4-dimethyl-5-sulfanilamido-isoxazole, formerly known as NU-445, is a new sulfonamide which has as its advantages a high degree of solubility and low toxicity. Because of its solubility, there is no crystallization in the urine except with doses that are much higher than would be used therapeutically.

Bryer and his associates1 reported that the acute toxicity of gantrisin® is low in white mice. They found the drug comparable to sulfadiazine in its ability to protect mice against beta hemolytic streptococcus and pneumococcus infections. It is not as effective as sulfadiazine in experimental infections in mice produced by Klebsiella pneumoniae. Neither compound was protective against experimental infection produced by Hemophilus influenzae, type B. Sarnoff2 reported neither crystalluria nor signs of renal irritation in 36 patients treated with gantrisin.® He observed that the amount of the drug entering into the spinal fluid of

Topics

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

First Page Preview

View Large
First page PDF preview

Figures

Tables

References

Correspondence

CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Submit a Comment

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Related Content

Customize your page view by dragging & repositioning the boxes below.

Jobs
brightcove.createExperiences();